Rallybio
Open
$8.98
Prev. Close
$9.02
High
$9.03
Low
$8.97
Market Snapshot
$46.89M
-5.2
-1.08
$848K
14
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
emptyResult
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Recently from Cashu
Rallybio's Innovative Therapies Target Rare Diseases: Progress and Future Goals for 2025
Rallybio Advances Innovative Therapies for Rare Diseases Rallybio Corporation, a clinical-stage biotechnology firm dedicated to developing treatments for rare diseases, highlights its significant achi…
Rallybio's Bold 2025 Goals for Advancing Rare Disease Therapeutics
Rallybio Sets Ambitious Goals in Rare Disease Therapies for 2025 Rallybio Corporation, a clinical-stage biotechnology firm specializing in therapies for rare diseases, showcases its commitment to inno…
Rallybio Showcases Promising Rare Disease Therapies at ASH Annual Meeting 2024
Rallybio Advances Research on Rare Disease Therapies at ASH Annual Meeting Rallybio Corporation, a clinical-stage biotechnology firm specializing in treatments for rare diseases, makes a significant i…
Rallybio Unveils Promising Therapies RLYB212 and RLYB332 at ASH Annual Meeting
Rallybio Showcases Innovative Therapies at ASH Annual Meeting Rallybio Corporation, a clinical-stage biotechnology company dedicated to developing therapies for rare diseases, highlights significant a…